This article first appeared on GuruFocus. Eli Lilly (LLY, Financials) says higher doses of Zepbound may have widened its weight-loss advantage over Novo Nordisk's Wegovy. Warning! GuruFocus has detected 2 Warning Sign with SPCX. Is LLY fairly valued? Test your thesis with our free DCF calculator.LLY GF Value chart A new indirect analysis found that patients receiving Zepbound 15 mg and 10 mg had 4.5 percentage points and 3.2 percentage points more weight loss, respectively, over 72 weeks than patients taking high-dose Wegovy. The difference was even more pronounced among people reaching larger weight-loss goals.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.